By John Lee.
Swedish biopharmaceutical company Xbrane has confirmed an additional order of Spherotide from Pooyesh Darou, its partner in the Middle East, to a value of SEK 8.5 million ($1.1 million) to be delivered in Q4 2017.
With this delivery Xbrane will meet its expected sales during 2017 of approximately SEK 20 million, as earlier communicated.
Spherotide was launched in Iran in July 2017 under the local brand name Microrelin® and since then more than 10,000 doses have been sold.
Martin Åmark (pictured), CEO of Xbrane comments:
“We are pleased to see that the sales of Spherotide locally in Iran is ramping up so quickly and that the product has received a positive response. We are happy to meet our expected sales during 2017 and we are looking forward to further increasing them during 2018.”